Every year, about one million new cases of colon cancer are diagnosed worldwide. About 150,000 new cases are detected each year in the United States. Over a lifetime, about 1 in 19 people develop colon cancer and nearly 50,000 people are expected to die from it in the U.S. this year. According to the American Cancer Society, colon cancer is the third leading cause of cancer-related death in the U.S., accounting for about 10 percent of all cancer deaths.
A new way to significantly increase the potency of almost any vaccine has been developed by researchers from the International Institute for Nanotechnology at Northwestern University.
Three years after the first negative multi-target stool DNA test, according to a scientific investigation into the best time to screen for colorectal cancer using non-invasive methods for detecting the disease’s targets in the stool, there were no colorectal malignancies discovered.
A dietary modification may be essential to improving colon cancer treatment, according to research from the University of Michigan Rogel Cancer Center.
The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.
Recent research discovered that bowel tumors can be classified into six clinically relevant subcategories based on patterns of gene interactions seen within tumor cells. The study was published in eLife.
Researchers at Mount Sinai’s Tisch Cancer Institute have discovered a new gene that is crucial to the development of colon cancer and established that inflammation in the region surrounding the tumor can contribute to the development of tumor cells.
Researchers from Wake Forest University School of Medicine have discovered a possible new approach to treating solid tumors through the creation of a novel nanoparticle. Solid tumors are found in cancers such as breast, head and neck, and colon cancer.
CAR T therapy, or chimeric antigen receptor T-cell therapy, has revolutionized the treatment of some blood cancers, allowing patients with relapsed or refractory disease to live longer and better lives.
A team of researchers at Sweden’s Karolinska Institutet studied how specific immune cells known as innate lymphoid cells (ILCs), which play a role in inflammatory bowel disease (IBD), evolve into mature cells.
Mutations in the APC gene cause the production of intestinal polyps in persons suffering from familial adenomatous polyposis, a genetic disease that predisposes them to colon cancer.
There are many proteins involved in the spread of cancer. However, some of them are notably difficult to observe in patient tissue samples.
According to research published in eLife, researchers have developed a pipeline for detecting, prioritizing, and testing potential tumor antigens for the rapid development of cancer vaccines.
Scientists develop a new fluorescent label that provides a sharper image of how DNA architecture is disturbed in cancer cells.
A recently published paper in the journal Molecular Cancer by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Genetics Chairman at the University of Barcelona, shows that transfer RNAs for certain amino acids are altered at the epigenetic level in some types of cancer, expressing it in an exaggerated manner in some cases and being deficient in others.
New studies emerge daily on the effect of the human microbiome on human health: colon cancer, ulcers, and cognitive conditions such as Alzheimer's disease have been associated with the communities of microbes that live in our bodies.
New clinical research indicates that a widely used food additive, carboxymethylcellulose, alters the intestinal environment of healthy persons, perturbing levels of beneficial bacteria and nutrients.
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.
A new study has discovered a two-arm molecule that can effectively deplete cancer-protecting cells within tumors.
Cell growth requires new proteins and the same applies to cancer cells. Scientists analyzed the protein eIF4A3 and its role in the growth of cancer cells.
Scientists and faculty of Vanderbilt University are in search of the “Achilles’ heel” of cancer cells that survive initial chemotherapy.